Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.41 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31277431 | 1.00 | LRRK2 (0.46) | LRRK2USP2LMNAHTTL3MBTL1 | |
| SCHEMBL22412007 | 0.90 | PTGER1 (0.47) | LRRK2USP2LMNAHTTALDH1A1 | |
| SCHEMBL3003359 | 0.88 | HDAC8 (0.48) | LRRK2HTTCTSVCTSLHDAC8 | |
| SCHEMBL23541164 | 0.82 | LRRK2 (0.49) | LRRK2USP2LMNAHTTL3MBTL1 | |
| SCHEMBL23270090 | 0.80 | CCR5 (0.46) | LRRK2USP2LMNAHTTCTSV | |
| SCHEMBL22412427 | 0.80 | HDAC8 (0.49) | LRRK2HTTCTSVCTSLHDAC8 | |
| SCHEMBL630140 | 0.79 | MEN1 (0.48) | LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL2897343 | 0.79 | SMN1; SMN2 (0.44) | LMNAHTTL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23540744 | 0.79 | LMNA (0.43) | LRRK2USP2LMNAHTTL3MBTL1 | |
| SCHEMBL31277078 | 0.79 | LMNA (0.43) | LRRK2USP2LMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116348455-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116332873-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114025844-B | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-112955438-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3810580-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20100197744-A1 | Organic Compounds | BARNES DAVID | 2010-08-05 | — | — | US | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-2155704-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| WO-2008148744-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963293-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067612-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | LRRK2 453/4885USP2 432/4885LMNA 4846/4885 |
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | LRRK2 338/4885USP2 753/4885LMNA 4839/4885 |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | LRRK2 359/4885USP2 854/4885LMNA 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.